Loading stock data…
Corvus Pharmaceuticals (CRVS)
$14.48+0.99 (+7.34%)
After Hours$14.23-0.25 (-1.73%)· Last close Jun 29
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Corvus Pharmaceuticals, Inc. in the Healthcare sector is trading at $14.48 with a market capitalization of $1.0B. Wall Street consensus targets $33.33 (6 analysts), implying a +130.2% move over the next 12 months. The stock is currently 46% below its 52-week high of $26.95, remaining 20.1% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +130.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.88M↓ | -$12.22M↓ | -$10.57M↓ | -$10.26M↓ | -$9.92M |
| Net Income | -$13.69M↓ | -$12.32M↓ | -$10.16M↓ | -$8.00M↓ | $15.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.00B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.35%
Volume
Today's trading volume
1.47M
Recent News
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Immuno-oncology specialist Corvus Pharmaceuticals reported a recent insider buy amid a year of sharp share price gains.
Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest
Corvus Pharmaceuticals (NasdaqGM:CRVS) reported promising Phase 1 results for its immunology drug candidate soquelitinib, with a favorable safety profile. The company has funding in place that it expects to last into Q2 2028, supporting further clinical development. Phase 2 data in atopic dermatitis for soquelitinib is anticipated, with investors watching for clarity on efficacy and future plans. These developments have led to discussion of Corvus Pharmaceuticals as a potential M&A target in...
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now?
Is CRVS a good stock to buy? We came across a bullish thesis on Corvus Pharmaceuticals, Inc. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on CRVS. Corvus Pharmaceuticals, Inc.’s share was trading at $11.15 as of June 8th. Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of […]
Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million
This cloud-based payments provider delivers SaaS solutions to enterprise billers across utilities, finance, and healthcare sectors.
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.